227 related articles for article (PubMed ID: 12208758)
1. Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance.
Volk EL; Farley KM; Wu Y; Li F; Robey RW; Schneider E
Cancer Res; 2002 Sep; 62(17):5035-40. PubMed ID: 12208758
[TBL] [Abstract][Full Text] [Related]
2. Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter.
Volk EL; Schneider E
Cancer Res; 2003 Sep; 63(17):5538-43. PubMed ID: 14500392
[TBL] [Abstract][Full Text] [Related]
3. Lack of an effect of breast cancer resistance protein (BCRP/ABCG2) overexpression on methotrexate polyglutamate export and folate accumulation in a human breast cancer cell line.
Rhee MS; Schneider E
Biochem Pharmacol; 2005 Jan; 69(1):123-32. PubMed ID: 15588721
[TBL] [Abstract][Full Text] [Related]
4. Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux.
Volk EL; Rohde K; Rhee M; McGuire JJ; Doyle LA; Ross DD; Schneider E
Cancer Res; 2000 Jul; 60(13):3514-21. PubMed ID: 10910063
[TBL] [Abstract][Full Text] [Related]
5. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells.
Honjo Y; Hrycyna CA; Yan QW; Medina-Pérez WY; Robey RW; van de Laar A; Litman T; Dean M; Bates SE
Cancer Res; 2001 Sep; 61(18):6635-9. PubMed ID: 11559526
[TBL] [Abstract][Full Text] [Related]
6. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2).
Jiao X; Zhao L; Ma M; Bai X; He M; Yan Y; Wang Y; Chen Q; Zhao X; Zhou M; Cui Z; Zheng Z; Wang E; Wei M
Breast Cancer Res Treat; 2013 Jun; 139(3):717-30. PubMed ID: 23780685
[TBL] [Abstract][Full Text] [Related]
7. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
Doyle L; Ross DD
Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
[TBL] [Abstract][Full Text] [Related]
8. Co-expression of cytokeratin 8 and breast cancer resistant protein indicates a multifactorial drug-resistant phenotype in human breast cancer cell line.
Liu F; Fan D; Qi J; Zhu H; Zhou Y; Yang C; Zhu Z; Xiong D
Life Sci; 2008 Sep; 83(13-14):496-501. PubMed ID: 18725232
[TBL] [Abstract][Full Text] [Related]
9. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
[TBL] [Abstract][Full Text] [Related]
10. MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2).
Ma MT; He M; Wang Y; Jiao XY; Zhao L; Bai XF; Yu ZJ; Wu HZ; Sun ML; Song ZG; Wei MJ
Cancer Lett; 2013 Oct; 339(1):107-15. PubMed ID: 23879965
[TBL] [Abstract][Full Text] [Related]
11. Selection and characterization of a high-activity ribozyme directed against the antineoplastic drug resistance-associated ABC transporter BCRP/MXR/ABCG2.
Kowalski P; Wichert A; Holm PS; Dietel M; Lage H
Cancer Gene Ther; 2001 Mar; 8(3):185-92. PubMed ID: 11332989
[TBL] [Abstract][Full Text] [Related]
12. BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells.
Yang CH; Schneider E; Kuo ML; Volk EL; Rocchi E; Chen YC
Biochem Pharmacol; 2000 Sep; 60(6):831-7. PubMed ID: 10930538
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin.
Rajendra R; Gounder MK; Saleem A; Schellens JH; Ross DD; Bates SE; Sinko P; Rubin EH
Cancer Res; 2003 Jun; 63(12):3228-33. PubMed ID: 12810652
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE
Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902
[TBL] [Abstract][Full Text] [Related]
15. Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer.
Yuan J; Lv H; Peng B; Wang C; Yu Y; He Z
Cancer Chemother Pharmacol; 2009 May; 63(6):1103-10. PubMed ID: 18820913
[TBL] [Abstract][Full Text] [Related]
16. [Regulation mechanism of breast cancer resistance protein by toremifene to reverse BCRP-mediated multidrug resistance in breast cancer cells].
Zhang YH; Li G; Yu J; Xu MS; Liu ZX
Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):654-60. PubMed ID: 22340044
[TBL] [Abstract][Full Text] [Related]
17. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines.
Ross DD; Yang W; Abruzzo LV; Dalton WS; Schneider E; Lage H; Dietel M; Greenberger L; Cole SP; Doyle LA
J Natl Cancer Inst; 1999 Mar; 91(5):429-33. PubMed ID: 10070941
[TBL] [Abstract][Full Text] [Related]
18. Resistance to mitoxantrone in multidrug-resistant MCF7 breast cancer cells: evaluation of mitoxantrone transport and the role of multidrug resistance protein family proteins.
Diah SK; Smitherman PK; Aldridge J; Volk EL; Schneider E; Townsend AJ; Morrow CS
Cancer Res; 2001 Jul; 61(14):5461-7. PubMed ID: 11454692
[TBL] [Abstract][Full Text] [Related]
19. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis.
Assaraf YG
Drug Resist Updat; 2006; 9(4-5):227-46. PubMed ID: 17092765
[TBL] [Abstract][Full Text] [Related]
20. Characterization of multidrug resistance-associated protein mRNAs expression profiles in Caco-2 and HT-1080 cell lines induced by methotrexate.
Ikeda K; Myotoku M; Hirotani Y
Pharmazie; 2008 Dec; 63(12):883-9. PubMed ID: 19177904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]